In this study, we introduce the AlzyFinder Platform, a unique web-based tool designed for virtual screening that uses an array of machine learning models built for over 85 key targets associated with Alzheimer's disease. The platform's user-friendly interface facilitates the execution of multiple virtual screening tasks, utilizing ligand-based drug design approaches. Results are showcased through drug-protein interaction networks (DPIs), which are instrumental in decoding the impact of potential therapeutics on biological systems by delineating the interactions between screened ligands and Alzheimer's disease-related targets.